1. Home
  2. CRUS vs NUVL Comparison

CRUS vs NUVL Comparison

Compare CRUS & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cirrus Logic Inc.

CRUS

Cirrus Logic Inc.

HOLD

Current Price

$144.04

Market Cap

7.1B

Sector

Technology

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$96.49

Market Cap

7.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRUS
NUVL
Founded
1984
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
7.8B
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
CRUS
NUVL
Price
$144.04
$96.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
15
Target Price
$149.60
$135.33
AVG Volume (30 Days)
459.2K
444.2K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
22.45
N/A
EPS
6.27
N/A
Revenue
$1,896,077,000.00
N/A
Revenue This Year
$6.27
N/A
Revenue Next Year
$1.84
$1,165.56
P/E Ratio
$23.74
N/A
Revenue Growth
5.99
N/A
52 Week Low
$75.83
$55.54
52 Week High
$154.90
$113.02

Technical Indicators

Market Signals
Indicator
CRUS
NUVL
Relative Strength Index (RSI) 57.57 41.61
Support Level $115.31 $73.71
Resistance Level $146.81 $107.13
Average True Range (ATR) 4.78 3.10
MACD 1.14 -0.06
Stochastic Oscillator 54.33 24.75

Price Performance

Historical Comparison
CRUS
NUVL

About CRUS Cirrus Logic Inc.

Cirrus Logic Inc is a provider of integrated circuits for audio and voice signal processing applications. The firm's products are organized into two streams: portable audio products, and HPMS Products. These products include aAmplifiers, codecs, smart codecs, analog-to-digital converters, digital-to-analog converters and standalone digital signal processors, Camera controllers, haptics and sensing solutions, and battery and power ICs. Roughly half of the firm's revenue is generated in China, with the rest coming from the United States, Europe, South Korea, and countries across the world.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: